Clinical experience with growth hormone treatment in patients with β- thalassaemia major

BioDrugs

Volumn 11, Issue 2, 1999, Pages 79-85

  De Sanctis, Vincenzo ^a   Urso, Luigina ^a  

^a Department of Paediatrics ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; IRON; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN;

BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH RETARDATION; HUMAN; IRON OVERLOAD; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REVIEW;

EID: 0033038214     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911020-00002     Document Type: Review

References (28)

1. Fessas P, Loukopoulos D. The beta-thalassaemias. Clin Haematol 1974; 3: 411-35
2. Wonke B. Management of beta-thalassaemia major. Curr Paediatr 1994; 4: 38-42
3. Rebulla P, Modell B. Transfusion requirements and effects in patients with thalassaemia major. Cooley care programme. Lancet 1991; 337: 277-80
4. De Sanctis V, Wonke B. Growth in thalassaemia. Farmaci 1994 Suppl.: 1-45
5. Bergeron C, Kovacs K. Pituitary and ultrastructural study. Am Pathol 1978; 93: 292-309
6. De Sanctis V, Atti G, Banin P, et al. Growth in thalassaemia major. Acta Med Auxol 1991; 23: 29-36
7. De Sanctis V, Stea S, Savarino L, et al. Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine. J Pediatr Endocrinol Metab 1998; 11 (5): 227-33
8. Vassilopoulou-Sellin R, Oyedejico, Foster PL, et al. Hemoglobin as a direct inhibitor of cartilage growth in vitro. Horm Metabol Res 1989; 21: 11-4
9. De Virgilis S, Congia S, Frau M, et al. Deferioxamine-induced growth retardation in patients with thalassaemia major. J Pediatr 1988; 113: 661-9
10. De Sanctis V, Urso L, Galati MC, el al. Growth hormone (GH) treatment in thalassamic patients with short stature, GH insufficiency and different severity of iron overload. Bone Marrow Transplant 1997; 19: 32-3
11. Vullo C, De Sanctis V, Katz M, et al. Endocrine abnormalities in thalassaemia. Ann N Y Acad Sci 1990; 612: 293-310
12. Pintor G, Cella SG, Manso P, et al. Impaired growth hormone (GH) response to GH-releasing hormone in thalassaemia major. J Clin Endocrinol Metab 1986; 62; 263-7
13. Shehadeh N, Hazani A, Rudolf MCJ, et al. Neurosecretory dysfunction of growth hormone secretion in thalassaemia major. Acta Paediatr Scand 1990; 79: 790-5
14. Saenger P, Schwartz E, Markenson AL, et al. Depressed serum somatomedin activity in beta-thalassiemia. J Pediatr 1980; 96: 214-8
15. Werther GA, Nathews RN, Burger HG, et al. Lack of response of non-suppressible insulin-like activity in thalassaemia major. J Clin Endocrinol Metab 1981; 53: 806-9
16. Herrington AC, Werther GA, Mathews RN, et al. Studies on the possible mechanism for deficiency of nonsuppresible insulin-like activity in thalassaemia major. J Clin Endocrinol Metab 1981; 52: 393-8
17. De Sanctis V, Pintor C, Gamberini MR, et al. Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin Endocrinol 1995; 42: 581-6
18. De Luca G, Maggiolini M, Bria M, et al. Valutazione della secrezione dell'ormone della crescita (GH) in soggetti affetti da thalassemia major. Minerva Endocrinol 1993; 18 Suppl.: 62-5
19. Di Martino J, Stoner E, Giardina PJ, et al. Effect of exogenous growth hormone in patients with thalassaemia major [abstract]. Pediatr Res 1985; 80: 900
20. Scacchi M, Danesi L, De Martin M, et al. Treatment with biosynthetic growth hormone of short thalassaemic patients with impaired growth hormone secretion. Clin Endocrinol 1991; 35: 335-9
21. Theodoridis C, Karis C, Ladis V, et al. Effects or recombinant human growth hormone on growth of thalassaemic children with G.H.D [abstract]. World Congress of Pediatrics; 1992 Jun 12-15; Rio de Janeiro, Brazil; 55: T914-11
22. Caruso-Nicoletti M, Mancuso M, Spadaro G, et al. Response to growth hormone treatment in thalassaemic patients [abstract]. 10th International Congress of Endocrinology (ICE '96); 1996 Sep 12-15; San Francisco: 765: P3-43
23. De Sanctis V, Urso L. L'accrescimento staturale nella talassemia. Minerva Pediatr 1997; 47: 121-8
24. Theodoridis C, Papatheodorou A, Karis C, et al. Short and long-term effect of rhGH on growth of short GH deficiency children with beta-thalassaemia [abstract]. 34th Annual Meeting of ESPE, Edinburgh. Horm Res 1995 Jun 25-28; 58: 228
25. Masala A, Alagna, S, Gallisai D, et al. GH secretion after bone marrow transplantation (BMT) in patients with homozygous beta-thalassaemia. J Clin Endocrinol Invest 1992; 15 Suppl. 1: 126
26. Low WK, Kwan EYW, Lim YJ, et al. Growth hormone treatment of short chinese children with beta-thalassaemia major without GH deficiency. Clin Endocrinol 1995; 42: 359-63
27. Low LCK. Growth, puberty and endocrine function in beta-thalassaemia major. J Ped Endocrinol Metab 1997; 10: 175-84
28. Frasier SD. Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr Rev 1983; 4: 155-60